Arbutus Biopharma Corporation（股票代码：ABUS）宣布，其研发的乙肝治疗药物Imdusiran已获得美国食品药品监督管理局（FDA）授予的快速通道资格，将用于慢性乙型肝炎的治疗。
这一重要监管里程碑有望加速该药物的审评进程，为患者提供更早获得创新疗法的可能。
Arbutus Biopharma Corporation（股票代码：ABUS）宣布，其研发的乙肝治疗药物Imdusiran已获得美国食品药品监督管理局（FDA）授予的快速通道资格，将用于慢性乙型肝炎的治疗。
这一重要监管里程碑有望加速该药物的审评进程，为患者提供更早获得创新疗法的可能。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.